ABL Bio Officially Invited to JP Morgan Healthcare Conference

Officially Invited for 7 Consecutive Years Since Establishment
Large Export of 'ABL301' Last January

Sanghoon Lee, CEO of ABL Bio / Photo by Chunhee Lee

[Asia Economy Reporter Chunhee Lee] Dual-antibody specialist company ABL Bio announced on the 27th that it has been officially invited to participate in the 41st JP Morgan Healthcare Conference, held from the 9th to the 12th of next month (local time). This marks the 7th official invitation, and ABL Bio has attended the event every year since its founding.

The JP Morgan Healthcare Conference, which began in 1983, is the world's largest pharmaceutical and bio healthcare event. More than 14,000 participants from around the world, including healthcare-focused investors, bio companies, and global pharmaceutical firms, gather to discuss research and development (R&D), investment attraction, partnerships, and more.

At the conference, ABL Bio plans to meet with global companies to introduce its dual-antibody technology and seek opportunities for technology transfer and partnership agreements. Discussions will cover various fields, including the ‘Grabody-B’ platform that enhances blood-brain barrier (BBB) permeability, as well as its immuno-oncology pipeline.

ABL Bio CI (Photo by ABL Bio)

In January, through this year's JP Morgan Healthcare Conference, ABL Bio signed a major deal worth $1.06 billion (approximately 1.343 trillion KRW) to license its dual-antibody candidate 'ABL301' for treating degenerative brain diseases such as Parkinson's disease to global big pharma Sanofi. The contract includes an upfront payment of $75 million and milestone payments totaling $985 million (with short-term milestones of $45 million), making it the second-largest technology export deal by a domestic company this year.

Lee Sang-hoon, CEO of ABL Bio, said, “We have been officially invited to attend the JP Morgan conference every year. Unlike before, now meeting requests flood in to the point that it is difficult to manage during the event, and many of the counterpart companies are well-known global firms, which makes us realize how much the company's status has changed.” He added, “Technology transfer requires long-term negotiations and mutual trust. Through this year's conference, we aim to conduct more advanced discussions and build even stronger trust.”

This content was produced with the assistance of AI translation services.